Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156962 | 1.00 | SRC (0.39) | SRCJAK2JAK1ABCB1RORC | |
| SCHEMBL5152621 | 0.89 | CYP1A2 (0.41) | SRCJAK2JAK1ABCB1MEN1 | |
| SCHEMBL5152627 | 0.89 | CYP1A2 (0.41) | SRCJAK2JAK1ABCB1MEN1 | |
| SCHEMBL29035403 | 0.89 | CYP1A2 (0.41) | SRCJAK2JAK1ABCB1MEN1 | |
| SCHEMBL28396275 | 0.89 | CYP1A2 (0.41) | SRCJAK2JAK1ABCB1MEN1 | |
| SCHEMBL5150301 | 0.89 | CYP1A2 (0.41) | SRCJAK2JAK1ABCB1MEN1 | |
| SCHEMBL15345576 | 0.89 | CYP1A2 (0.41) | SRCJAK2JAK1ABCB1MEN1 | |
| SCHEMBL13309095 | 0.88 | SRC (0.38) | SRCJAK2JAK1ABCB1MEN1 | |
| SCHEMBL5151940 | 0.88 | SRC (0.40) | SRCJAK2JAK1ABCB1MEN1 | |
| SCHEMBL5152054 | 0.88 | SRC (0.40) | SRCJAK2JAK1ABCB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | SRC 2660/4885JAK2 897/4885JAK1 1444/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | SRC 2615/4885JAK2 910/4885JAK1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.